Peapod Lane Capital LLC Sells 78,003 Shares of Kyverna Therapeutics, Inc. $KYTX

Peapod Lane Capital LLC reduced its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 19.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 318,760 shares of the company’s stock after selling 78,003 shares during the period. Kyverna Therapeutics comprises approximately 1.7% of Peapod Lane Capital LLC’s portfolio, making the stock its 24th biggest holding. Peapod Lane Capital LLC’s holdings in Kyverna Therapeutics were worth $1,912,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in KYTX. Phoenix Wealth Advisors bought a new position in shares of Kyverna Therapeutics in the 2nd quarter valued at about $32,000. Catalyst Funds Management Pty Ltd purchased a new stake in Kyverna Therapeutics during the second quarter valued at approximately $37,000. Qube Research & Technologies Ltd bought a new stake in shares of Kyverna Therapeutics in the 2nd quarter valued at approximately $43,000. Ethic Inc. purchased a new position in shares of Kyverna Therapeutics in the 2nd quarter worth approximately $56,000. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of Kyverna Therapeutics by 25.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 19,122 shares of the company’s stock valued at $59,000 after purchasing an additional 3,847 shares during the last quarter. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Kyverna Therapeutics Stock Down 5.2%

Kyverna Therapeutics stock opened at $7.68 on Monday. The firm has a market cap of $336.38 million, a P/E ratio of -2.06 and a beta of 3.45. The business has a fifty day moving average of $8.47 and a two-hundred day moving average of $6.80. Kyverna Therapeutics, Inc. has a twelve month low of $1.78 and a twelve month high of $13.67.

Insider Activity at Kyverna Therapeutics

In other Kyverna Therapeutics news, CTO Karen Marie Walker sold 23,998 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $12.20, for a total value of $292,775.60. Following the completion of the sale, the chief technology officer directly owned 22,636 shares in the company, valued at $276,159.20. This trade represents a 51.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Biopartners Opportuni Westlake purchased 133,333 shares of the business’s stock in a transaction on Thursday, December 18th. The stock was purchased at an average cost of $7.50 per share, for a total transaction of $999,997.50. Following the completion of the acquisition, the insider directly owned 869,317 shares of the company’s stock, valued at approximately $6,519,877.50. The trade was a 18.12% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Wall Street Analyst Weigh In

Several brokerages have issued reports on KYTX. Wells Fargo & Company boosted their target price on Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Morgan Stanley set a $33.00 target price on shares of Kyverna Therapeutics in a research note on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Monday, December 29th. Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Finally, HC Wainwright raised their price objective on Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Kyverna Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $28.67.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.